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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).SUMMARYBone marrow stromal cells (BMSCs, also called bone-marrow-derived mesenchymal stromal cells) provide hematopoietic support and
immunoregulation and contain a stem cell fraction capable of skeletogenic differentiation. We used immortalized human BMSC clonal
lines for multi-level analysis of functional markers for BMSC subsets. All clones expressed typical BMSC cell-surface antigens; however,
clones with trilineage differentiation capacity exhibited enhanced vascular interaction gene sets, whereas non-differentiating clones
were uniquely CD317 positive with significantly enriched immunomodulatory transcriptional networks and high IL-7 production.
IL-7 lineage tracing and CD317 immunolocalization confirmed the existence of a rare non-differentiating BMSC subtype, distinct
from Cxcl12-DsRed+ perivascular stromal cells in vivo. Colony-forming CD317+ IL-7hi cells, identified at 1%–3% frequency in hetero-
geneous human BMSC fractions, were found to have the same biomolecular profile as non-differentiating BMSC clones using Raman
spectroscopy. Distinct functional identities can be assigned to BMSC subpopulations, which are likely to have specific roles in immune
control, lymphopoiesis, and bone homeostasis.INTRODUCTION
Bone marrow stromal cells (BMSCs, also called bone-
marrow-derived mesenchymal stromal cells) are hetero-
geneous populations that likely contain varying levels
of tripotent (osteogenic, adipogenic, and chondrogenic
[OAC]) stem-cell-like cells; cells with restricted potency
(bi-, uni-, and nullipotent), committed precursors, and
other stromal cell types. Phenotypic variations probably
reflect in vivo functional diversity and a biological require-
ment for distinct stromal subsets with specific roles in
bonemarrowmaintenance. Single-cell-derived BMSC clone
analysis has identified considerable variation in differentia-
tion capacity, ranging fromOAC tripotency to nullipotency
in vitro (Muraglia et al., 2000; Okamoto et al., 2002; Russell
et al., 2010, 2011) and in vivo (Kuznetsov et al., 1997),
which may indicate the existence of BMSC subtypes with
varied potencies and/or a hierarchical developmental pro-
gression. BMSCs also possess significant immunomodula-
tory characteristics and can influence all aspects of immune
cell function via cell-cell interaction and immunoregulatory
factor secretion (Nauta and Fibbe, 2007), although clear
demarcation between the skeletogenic and immunomodu-
latory capacity of BMSCs has not been made. Identification
of human BMSCs often relies on non-discriminatory
epitope detection (such as CD29, CD44, CD73, CD901004 Stem Cell Reports j Vol. 4 j 1004–1015 j June 9, 2015 j ª2015 The Aut[THY-1], CD105, CD106 [VCAM-1], and CD166) with lack
of hematopoietic markers (such as CD34, CD14, and
CD45) (Dominici et al., 2006). Additional BMSC surface an-
tigens have been described, including STRO-1 (Simmons
and Torok-Storb, 1991), CD146 (MCAM) (Sacchetti et al.,
2007), CD271 (LNGFR) (Quirici et al., 2002), Nestin (Me´n-
dez-Ferrer et al., 2010), platelet-derived growth factor recep-
tor alpha (PDGFRa)/CD51 (Pinho et al., 2013), LNGFR+THY-
1+VCAM-1hi+ (Mabuchi et al., 2013), and in mice, leptin
receptor (LepR/CD295) (Zhou et al., 2014). However, cell-
sorting experiments using these markers all show that
they contain the colony-forming, differentiation-compe-
tent BMSC population, demonstrating that other, as yet
undefined BMSC subtypes exist and further resolution of
BMSC heterogeneity is required. In vitro studies of BMSC
functionality are hindered by their limited lifespan as
replicative senescence occurs during culture, thus limiting
the number and depth of studies that can be performed.
To address these issues, we immortalized human BMSCs
using human telomerase reverse transcriptase (hTERT),
followed by clonal isolation to generate a panel of BMSC
lines (hTERT-BMSCs). This strategy enabled in-depth,
multiparameter analysis of variation in human BMSC
subpopulations with different behavioral traits that sub-
sequently could be examined in heterogeneous primary
BMSCs. We unveil a range of biophysico-chemical markershors
for identification of different BMSC subsets with specific
immunomodulatory and differentiation competencies.RESULTS
Generation and Phenotyping of Variant hTERT
Immortalized Clonal Cell Lines from Primary BMSCs
A heterogeneous population of primary bone marrow
BMSCswas isolated from one donor (FH181) based on their
strong growth properties and multilineage differentiation
potential. A single donor was deliberately selected to guard
against expected genetic/lifestyle factors that cause inter-
donor variation and would cloud interpretation of BMSC
sub-population variation. A lentiviral expression system
was used to overexpress hTERT in these cells, and stable-
expressing lines were generated from single-cell-derived
colonies. From numerous hTERT-BMSCs generated, our
attention focused initially on four clonal lines selected for
their strong clonal and stable growth characteristics
(termed Y101, Y102, Y201, and Y202) that were main-
tained for over 400 days, showing exponential growth (Fig-
ure S1A) and elevated telomerase activity (Figure S1B).
Their BMSCmarker profile was determined by flow cytom-
etry; all were positive for CD29, CD44, CD73, CD90,
CD105, and CD166 and negative for CD34 and CD45
(Figure 1A), a profile matching their parental cells and
typical of human primary BMSCs. All clones were also
negative for CD11b, CD14, CD169, CD1a, CD4, CD11c,
and CD83 (data not shown). It has been suggested
previously that some BMSC lines may undergo oncogenic
transformation either through hTERT transduction or
extended time in culture (Serakinci et al., 2004). We found
no evidence of tumorigenicity in our hTERT-BMSCs using
in vitro colony transformation assays for non-adherent
growth (Figure S1C) or following subcutaneous injection
into immunocompromised mice (data not shown).
Distinct differences were observed in individual cell mor-
phologies and single-cell-derived colonies: Y101 and
Y201 shared characteristics that were distinct from Y102
and Y202 lines. Y101 and Y201 lines had elongated fibro-
blastoid morphology, typical of BMSCs, whereas Y102
and Y202 were flattened and spread.When plated at clonal
density, Y101/Y201 cells consistently formed dispersed col-
onies with low cell contact, characteristic of a migratory
phenotype, whereas Y102 and Y202 cells formed regular,
high-density, compact colonies (Figures 1B and S1D).
Morphological differences were quantified by image anal-
ysis, which demonstrated that Y202 cells had a statistically
significantly greater area and perimeter compared to both
the Y101 and Y201 cells. Y102 cells were also larger than
the Y101/Y201; the mean cell perimeters for Y102, Y202,
Y101, and Y201 were 273 ± 23, 317 ± 107, 202 ± 19, andStem C190 ± 34 mm, and mean cell areas were 1,537 ± 132,
1,649 ± 614, 1,067 ± 92, and 857 ± 214 mm2, respectively
(Figures S1E and S1F).
We identified variations in potency following OAC dif-
ferentiation assays (Figures 1C–1E). Adipogenic media for
up to 21 days induced the most potent observable and sta-
tistically significant adipogenic differentiation in Y201
cells at each time point, measured using the oil red O
lipid-staining assay (Figure 1C). Y101 was also observed
to differentiate into adipocytes, reaching significance at
day 21, but Y102 and Y202 showed severely limited,
although not completely absent, adipogenic potential,
whichwas significantly different to Y201 at day 21. In addi-
tion, there were statistically significant increases in the
levels of expression of the adipogenic genes peroxisome
proliferator-activated receptor (PPAR)-g and lipoprotein
lipase (LPL) in the Y201 cells cultured in adipogenic media
at day 14 and day 21 compared to the time-matched un-
treated controls. At day 21, the expression level of both
these genes was significantly lower in the three other cell
lines (Figure 1C). Y101 and Y201 differentiated convinc-
ingly along osteogenic lineages and showed elevated alka-
line phosphatase (ALP) activity with significantly increased
calcium deposition by alizarin red staining (Figure 1D),
which was statistically higher than Y102/Y202 clones,
which showed minimal mineral deposition, although
Y102 displayed elevated ALP activity (Figure 1D). Increases
in ALP activity observed under basal conditions for Y101
and Y201 were replicated in qPCR analyses of the ALP
gene (Figure S1G); further increases in ALP gene expression
were clearly evident in the Y101 cell line under osteogenic
conditions, while the levels in the other lines only showed
modest increases. Furthermore, histological staining for
elevated ALP activity was only observable in the Y101/
Y201 cells (Figure S1G). Gene expression analyses for
RUNX2 showed that only the Y101/Y201 cell lines upregu-
lated this early osteogenic marker at day 7 (Figure 1D). In
response to chondrogenic induction using transforming
growth factor b (TGF-b), only lines Y101 and Y201 dis-
played an early cell-condensation phenotype associated
with chondrogenic induction (Johnson et al., 2012),
whereas no condensation was observed in similar micro-
mass culture of lines Y102 and Y202 (Figure 1E). When cul-
tures were stained with alcian blue and stain-associated
glycosaminoglycans (GAGs) were eluted and quantified,
significantly different levels were observed in all cell lines
at day 9 compared to their time-matched controls under
basal conditions, but the highest and statistically signifi-
cant GAG levels were clearly evident in the Y101/Y201
compared to the Y102/Y202 cell lines. Similarly, only the
Y101 and Y201 lines displayed marked increases in total
GAG production under chondrogenic conditions in the
Blyscan GAG assay (Figure 1E). Gene expression analysesell Reports j Vol. 4 j 1004–1015 j June 9, 2015 j ª2015 The Authors 1005
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for the early chondrogenic marker SOX9 confirmed that
this marker only increased in the Y101/Y201 cell lines after
7 days in chondrogenic differentiation media (Figure 1E).
Therefore, lines Y101/Y201were capable of BMSCOAC dif-
ferentiation, with Y201 showing stronger adipogenesis.
The Y102/Y202 BMSC lines exhibited a non-hematopoiet-
ic, stromal phenotype with distinctive clonal behavior but
with atypical BMSC morphology and limited differentia-
tion ability compared to Y101/Y201.
Interrogation of Gene Expression Profiles Identifies
Immune-Related BMSC Subtypes
We performed global gene expression analyses to identify
distinguishing characteristics between the hTERT-BMSC
clones and parental BMSCs; selecting significantly differen-
tially expressed genes (p < 0.05, >2-fold change). Hierarchi-
cal clustering grouped Y101 with Y201 and closest to the
primary parent BMSCs, while Y102/Y202 clustered sepa-
rately (Figure 2A). Principal component analysis (PCA)
revealed that 70% of the total variance was captured by
the first two components (Figure S2A) and confirmed segre-
gation of Y102/Y202 BMSC lines from the Y101/Y201
BMSC lines, the parent BMSC (FH181), and other primary
BMSC populations (Figure S2B). Pathway analysis identi-
fied significant differences in expression of genes involved
in the cell cycle, DNA replication, and other processes
associated with cell replication, as would be predicted
when comparing hTERT-immortalized lines with the
parent sample (Figure 2B). Additional gene sets identified
were involved in cell adhesion, endochondral ossification,
and adipogenesis. Differentially expressed genes were
notably enriched in pathways involved in Toll-like recep-
tor, interferon, tumor necrosis factor a (TNF-a), inter-
leukin-7 (IL-7) signaling, and inflammatory responses,
implicating potential differences in the immunoregulatory
properties between these lines (Figure 2B). Patterns of gene
expression were also visualized and investigated using self-
organizing heatmaps (SOMs). Expression data were used to
produce mosaic fingerprints, and each mosaic tile repre-
sents metagenes that consist of mini-clusters of genesFigure 1. Generation and Analysis of hTERT-BMSC Clones
(A) Analysis of hTERT-BMSC clones (Y101, Y102, Y201, and Y202) b
Representative histograms are shown.
(B) Clonal growth of hTERT-BMSCs (crystal violet stain). Scale bars, 2
(C–E) Assessment of the OAC potential of hTERT-BMSC clones; repr
adipogenic (C), osteogenic (D), and chondrogenic supplements (E).
average quantified values ± SD for two or three independent exper
considered to be statistically significant after the data from n > 3 exper
comparisons if *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0
Additionally, one-way ANOVA with Holm Sidak’s comparisons was pe
differences compared with Y101 () or Y102 ($) and Y201 (#) are in
See also Figure S1.
Stem Cwith similar expression placed in the same position across
the mosaics (Figure 2C). Y101, Y201, Y102, and Y202 were
compared against the primary parent BMSC source
(FH181) and four others (FH469, FH348, FH359, and
FH392). Primary BMSCs showed consistent spots of strong
over- and under-expression in the bottom-right and
top-left corners, respectively. Y101/Y201 and Y102/Y202
hTERT-BMSCs showed differences in patterns of expression
at regions of over- and under-expression in the top right
and bottom left of the SOMs, respectively (Figure 2C,
arrows, and Figures S2C and S2D). The most significant
gene sets overexpressed in Y101/201 versus Y102/202
were related to vascular growth (blood vessel remodelling,
blood vessel development, artery morphogenesis, and
patterning of blood vessels; Figure S2C). Under-expressed
Y101/Y201 gene sets that were most significantly over-rep-
resented in Y102/Y202 lines were immunomodulatory (an-
tigen processing, MHC class II proteins, T cell signaling,
and responses to interferon; Figure S2D).
Further analysis found a strikingly elevated endogenous
expression of inflammation-induced genes in the non-
differentiating lines Y102 and Y202 compared to the
OAC-differentiation-competent BMSC clones (Figure 2D).
By analyzing gene expression changes reported in a previ-
ously published dataset, where global gene expression
was studied in adipose-derived BMSCs with or without
stimulation with inflammatory cytokines (interferon g
[IFN-g], TNF-a, and IL-6) (Crop et al., 2010), we found
that inflammation-induced genes were also elevated in un-
stimulated Y102 and Y202 cells compared to the Y101/
Y201 and parental BMSCs (Figure 2D). These observations
pointed to the existence of a non-differentiating, resident
stromal cell subset with ‘‘unlicensed’’ immunoregulatory
potential associated with a pro-inflammatory response.
The immunomodulatory effects of BMSCs are normally
reported to be related to immunosuppression. In assays of
immunosuppressive function, we found that all hTERT-
BMSC lines were similarly capable of inhibiting anti-
CD3/anti-CD28 antibody-stimulated peripheral blood
mononuclear cell (PBMC) proliferation with no significanty flow cytometry for surface markers typically assigned to BMSCs.
00 mm.
esentative images and quantification of cells differentiated with
Scale bar represents 200 mm (C and D) or 2 mm (E). Data represent
iments performed using two to six replicates. Differentiation was
iments were analyzed by one-way ANOVA with Holm Sidak’s multiple
.0001 between both day 0 and the time-matched basal control.
rformed between the different cell lines at day 21, and significant
dicated.
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Figure 2. Expression Profiling Identifies BMSC Clones with Distinct Immunoregulatory Features
(A) Hierarchical clustering heatmap of global gene expression profiles from each hTERT-BMSC clonal line and the parental BMSCs.
(B) Pathway analysis showing most significantly enriched pathways.
(C) Self-organizing heatmaps of the four hTERT-BMSC clones and five primary BMSC samples, including the parent population (FH181).
Arrows indicate presence (closed) and absence (open) of overrepresented (red) and underrepresented (blue) metagene spots.
(D) Heatmap showing expression of key genes involved in inflammatory-induced responses.
(legend continued on next page)
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differences of the inhibitory capacity of the cell lines at
each BMSC:PBMC ratio used (Figure S2E). Similar increases
in the expression of immunosuppressive factors (IDO1,
TGFB1, and CD274) following exposure to TNF-a and
IFN-g were observed in all hTERT-BMSC lines, but IL6
expression was significantly higher in the Y201 cells under
TNF-a/IFN-g stimulation (Figure S2F). Y102/Y202 cells
were significantly more responsive to inflammatory cyto-
kine-induced expression of factors involved in lymphocyte
homing and development, CXCL10 and IL-7. In particular,
basal mRNA expression of IL-7 in Y102/Y202 cells was
equivalent to expression levels in TNF-a/IFN-g-stimulated
Y101/Y201 cells (Figure S2F). IL-7 signaling was high-
lighted as a differentially regulated pathway (Figure 2B),
and we identified strong expression of IL-7 in Y102/Y102
compared to low IL-7 levels in Y101/Y201 by immunocyto-
chemistry (Figure 2E). Using ELISAs, we confirmed signifi-
cantly higher secretion of IL-7 in Y102/202 versus Y101/
Y201; heterogeneous primary BMSCs secreted low levels
of IL-7, with negligible expression in human dermal fibro-
blasts (Figure 2F). No difference in IL-7 receptor expression
level was observed by flow cytometry across the four cell
lines (data not shown).
Together, these data indicate that OAC-competent BMSC
clones expressed an extensive gene set consistent with
vascular interaction; all BMSC lines showed broadly similar
immunosuppressive features, while the poorly differen-
tiating hTERT-BMSCs displayed a striking constitutive
immunostimulatory expression profile and could be iden-
tified by elevated basal IL-7 expression, which has impor-
tant functions in lymphopoiesis (Ceredig and Rolink,
2012).
In Vivo Lineage Tracing of IL-7-Expressing Stromal
Cells
To identify and track IL-7-positive BMSC subpopulations
in vivo, we used an IL-7Cre Rosa26-EYFP lineage-tracing
mouse model, where enhanced yellow fluorescent protein
(EYFP) expression persists in the progeny of cells that
expressed IL-7 at any stage. EYFP-positive cells were found
in bonemarrow occasionally at perivascular and endosteal-
lining locations but broadly distributed throughout the
marrow with an 4% frequency (Figures 3A–3F and S3A).
Using flow cytometry to discriminate CD45-expressing
hematopoietic cells, we found the EYFP-positive stromal
fraction represented 0.9% of the marrow cell population(E) Immunocytochemical detection of IL-7 expression (red) by the
counterstain in blue). Scale bars, 20 mm.
(F) IL-7 expression by ELISA in the four hTERT-BMSC clones, primary B
Data represent mean values ± SD from three individual experiments p
See also Figure S2.
Stem C(Figure S3B). From histological sections, 91%, 77%, and
92%, respectively, of femoral, tibial, and calvarial osteo-
cytes, terminally differentiated cells of the osteogenic line-
age (Figures 3D–3F and S3A), and all perilipin-positive bone
marrow cells and all adipocytes in white adipose tissue
examined were EYFP negative (Figures 3G–3L and S3C).
Strong EYFP positivity was confirmed in 11%–60% of artic-
ular chondrocytes (Figures 3M–3O and S3A), where IL-7
expression has been previously identified (Long et al.,
2008), and in 7%–31% of hypertrophic chondrocytes (Fig-
ure S3A). These data demonstrate that a substantial propor-
tion of mesodermal-derived adipose, bone, and cartilage
tissues originate from a progenitor cell type that at no point
expressed IL-7 and support the existence of poorly/non-
differentiating IL-7hi BMSC subtype in vivo.
Identification of Y102/Y202-Related Subtypes in
Primary BMSCs
Y101/Y201 and Y102/Y202 lines were screened by flow
cytometry in an attempt to identify a distinguishing
cell-surface protein to sort from primary BMSC popula-
tions. We found little difference in expression of candidate
BMSC markers CD271, CD51, and PDGFRa; while CD146
was largely undetectable on the Y201 line, its expres-
sion was similar in the other BMSC clones (Figure 4A).
LepR/CD295 was expressed by both OAC-differentiating
lines and the differentiation-incompetent lines (Figure 4A);
in murine bone marrow, LepR/CD295 expression was
found to be predominantly, though not exclusively, ex-
pressed by bone- and adipocyte-forming BMSCs (Zhou
et al., 2014).
We analyzed the array data for differential expression
of genes encoding cell-surface proteins; while ICAM1
and CD274 had similar protein expression profiles across
all lines, CD317 was selectively and highly expressed in
Y102 and Y202 cells and absent from Y101 and Y201
cells (Figure 4A). We examined another four BMSC
clones (Y204, Y205, Y301, and Y302) generated during
the initial hTERT immortalization experiments (Fig-
ure S4A). They exhibited varying degrees of differentia-
tion potency (Figures S4B–S4H), but none were differen-
tiation incompetent across osteogenic, adipogenic, and
chondrogenic lineages to the same degree as observed
for Y102/Y202, and all were negative for CD317 (Fig-
ure S4I). CD317 (also known as BST2/tetherin) has re-
cognized anti-viral properties (Hotter et al., 2013), andfour hTERT-BMSC clones (after 24 hr in culture) (DAPI nuclear
MSCs (K98, K102, and K110), and human dermal fibroblasts (HDF).
erformed in duplicate.
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Y102/Y202 cells expressed elevated levels of several other
anti-viral genes compared to Y101/Y201 and parent
BMSCs (Figure 4B).
In low passage, primary BMSCs, a CD317-expressing
population was detected in 1%–3% of the total cells (Fig-
ure S4J). We used fluorescence-activated cell sorting (FACS)
to sort the CD317+ fraction from CD317 cells for further
analysis and found that CD317+ cells were capable of
density-independent growth and formed CFU fibroblasts
(CFU-F) at a frequency similar to CD317 cells (Figure 4C).
Morphological analysis of individual colonies identified
that CD317+ cells had statistically significantly increased
cell perimeters (1,042 ± 309 mm) and areas (5,355 ±
1,306 mm) compared to CD317 cells (1,386 ± 638 mm
and 330 ± 154 mm, respectively) (Figures 4D and S4K), mir-
roring Y102/Y202 versus Y102/Y201 size differences. Using
qPCR and ELISA, we confirmed that CD317+ BMSCs
expressed significantly elevated IL-7 mRNA and secreted
more IL-7 protein than the CD317 population (Figure 4E),
with limited evidence that CD317+ cells have elevated
basal mRNA expression levels of immunosuppressive fac-
tors compared to CD317 cells (Figure S4L), while exposure
of primary BMSCs to IFN-g for 24 hr resulted in an 3-fold
increase in CD317 expression (Figure S4M). As marker
expression can change with time in culture, we also sorted
CD317-expressing cells from fresh, whole human bone
marrow mononuclear cells (BM-MNCs); CD317+ cells in
the stromal CD45CD31 population represented on
average 0.4% of the live cell population from two donors
(Figures S4N and S4O).
In mouse tissue sections, CD317 was expressed sporadi-
cally throughout the bone marrow (Figures 4F and S4P;
isotypecontrol is showninFigureS4Q).CD317-positive cells
rarely associated with CD31-positive vascular cells (Figures
4F and S4P) and did not generally colocalize with Cxcl12-
DsRed+perivascular stromalandendothelial cells (Figure4F).
The majority of bone marrow LepR-expressing cells lacked
CD317 expression, though occasional LepR+CD317+ cells
were identified (Figure 4G).
Collectively, these findings identify the presence of a
rare, colony-forming population of BMSCs, marked by
CD317 positivity, which appear to have an enhanced im-
munostimulatory capacity and are closely related to the
Y102 and Y202 phenotype. We employed Raman spec-Figure 3. Lineage Tracing of IL-7-Expressing Cells Using IL-7cre
(A–F) Sporadic EYFP expression throughout bone marrow, associate
prominent on endosteal surfaces (B). Infrequent osteocytes were EYF
(G–J) Immunostaining of perilipin-positive adipocytes (red) in bone
(K and L) Absence of EYFP expression in white adipose tissue extract
(M–O) EYFP expression in chondrocytes of articular cartilage.
Scale bars, 50 mm (unless otherwise stated). See also Figure S3.
Stem Ctroscopy to determine the extent of this relationship
and provide a diagnostic evaluation of functional varia-
tion between BMSC subtypes. Averaged spectra were
generated for each hTERT clonal line and primary
CD317+ sorted BMSCs (Figure 4H), with their respective
peak assignments identified as described previously (Mo-
vasaghi et al., 2007; Schulze et al., 2010). Peak intensity
ratios were obtained between all identified peaks for
each cell type; the most discriminatory was found to be
against the 1,088.6 cm1 peaks. The 1,088.6 cm1 peak
is related to the symmetric phosphate stretch of the
DNA backbone (Movasaghi et al., 2007) with its discrimi-
nation signifying a fundamental difference in the DNA of
the cell types. This peak has also been used to discrimi-
nate other cell types, (Chan et al., 2006). The 966cm-1/
1088.6 cm1 peak intensity ratios distinguished Y101
from Y201 (Figure 4I, arrow). Other peak intensity ratios,
most notably from 999.6 cm1 and higher, clearly sepa-
rated Y101/Y201 from Y102/Y202 (Figure 4I). Impor-
tantly, primary CD317+ cells mapped with remarkable
consistency to the Y102/Y202 Raman profile (Figure 4I),
providing strong evidence of relatedness.DISCUSSION
We generated immortalized BMSC clones to perform
detailed analysis of functional diversity in BMSC subtypes
to levels not previously described. Similar immortalization
techniques (e.g., hTERT combined with human papilloma-
virus E6/E7) have been used for the clonal analysis of
BMSCs, which found OAC, AO, OC, unipotent, and nulli-
potent clones at varied frequencies, but other functional
characteristics and discriminating features were not exam-
ined (Larsen et al., 2010; Okamoto et al., 2002). Notably,
however, enhanced immune-related features could be as-
signed to non-bone-forming hTERT-BMSCs in a previous
study (Larsen et al., 2010). Using non-immortalized
BMSC clones, Muraglia et al. identified OAC-, OC-, and
O-competent lines only, with very rare (<1%) nullipotent
subsets (Muraglia et al., 2000). Rather than determine
occurrence of O/A/C phenotypes in heterogeneous BMSCs,
here our aim was to identify molecular and biophys-
ical markers of BMSC subtypes and their alignment withRosa26-EYFP Mice
d occasionally with cells lining the vasculature (A, arrows) and
P positive (D–F).
marrow of IL-7cre Rosa26-EYFP mice.
ed from IL-7cre Rosa26-EYFP mice.
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Figure 4. Identification of CD317+ Bone Marrow Cells
(A) Flow cytometric analysis of hTERT-BMSC; CD317 expression selectively discriminates Y102/Y202 from Y101/Y201.
(B) Heatmap showing expression of key genes involved in anti-viral responses.
(C) CFU-F assay and morphology of CD317 and CD317+ cells sorted from heterogeneous BMSCs. Scale bars, 200 mm. Histogram represents
mean ± SEM (n = 4 independent experiments performed with five replicates).
(legend continued on next page)
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non-progenitor cell functions, including immunomodula-
tory properties. To this end, from the original hTERT-BMSC
lines generated, we selected four clones positioned at
opposing ends of a differentiation competency scale, tripo-
tent Y101/Y201 and relatively impotent Y102/Y202, for
in-depth cell profiling. The OAC-differentiating lines ex-
pressed an extensive and significantly enriched gene set
consistent with blood vessel support/interaction compared
to nullipotent clones. This may reflect a relationship be-
tween BMSC differentiation competency and a perivascu-
lar niche location (Sacchetti et al., 2007). Conversely,
Y102 and Y202 lines expressed CD antigens widely used
to describe BMSCs (Dominici et al., 2006; Pittenger et al.,
1999) but exhibited very little differentiation capacity. Sub-
sequent assays revealed that an equivalent CD317+ cell
type existed in heterogeneous primary BMSC populations
at1%–3% frequency and CD45CD31CD317+ cells rep-
resented 0.4% of whole human BM-MNCs. Primary cell
analysis and in vivo validation is an important component
of our study. Data obtained using in vitro immortalized cell
lines must be interpreted with some caution, considering
the effects of hTERT transduction artifacts. Integration
site, enhanced telomerase activity and long-term culture
are all likely to impact on cell function. We attempted to
minimize potential confounding effects by selecting two
cell lines, each displaying similar properties (Y101/Y201
and Y102/Y202). We used Raman spectroscopy, which
has been demonstrated as a non-destructive label-free
method to study the biological state of single cells and to
identify molecular-scale differences for cell discrimination
(see Schulze et al., 2010, for example). In this work,
Raman spectroscopy was able to uniquely identify the
four hTERT-BMSC clones, separating Y101 from Y201
and confirming a striking biomolecular relationship
between Y102/Y202 and primary CD317+ cells, which
also shared an enlarged, spread morphology, forming
compact, non-migratory colonies. We performed detailed
bioinformatics to scrutinize gene expression profiles
against the parental BMSCs. These analyses ultimately
identified the closely clustered Y102 and Y202 lines as
having remarkably high basal level expression of factors(D) Analysis of cell perimeter (left) and cell area (right) of CD317 and
independent experiments in which, on average, 113 cells were exami
(E) IL-7 mRNA (left) and protein expression (right, by ELISA) in CD3
FACS-sorted cells in triplicate from four or two donors, respectively.
(F) Immunohistochemistry of mouse femur bone marrow sections stain
(white) and nuclear (DAPI, blue) staining. Representative merged an
(G) Immunolocalization of LepR/CD295 (green) and CD317 (red) in m
sional dual LepR+CD317+ cells (lower panel). Blue indicates nuclear D
(H and I) Analysis of hTERT-BMSC clones and CD317+ cells by Raman sp
peak assignments are provided in Table S2.
See also Figure S4.
Stem Cassociated with a pro-inflammatory and anti-viral func-
tion. The significantly enriched gene sets we identified
in unchallenged Y102/Y202 BMSC lines are typical of an
immediate immunostimulatory response to infection
and other insults. Notably, all BMSC clones exhibited
similar inhibitory effects on PBMC proliferation when
activated by exposure to anti-CD3 and anti-CD28 tomimic
antigen presentation. Consequently, Y102/Y202 BMSC
subtypes may function in both immunostimulatory (early,
pro-inflammatory) and immunosuppressive (anti-inflam-
matory, tissue protective) responses depending on the im-
mune environment; however, functional validation and
further refinement of the characteristics of this CD317-ex-
pressing population is required. Dual immunomodulatory
functions for BMSCs have been identified and discussed
(Dazzi and Krampera, 2011), but not assigned to BMSC
subtypes. CD317+ cells (as well as Y102/Y202) were charac-
terized as having elevated IL-7 expression, which has well-
established roles in T and B cell development (Ceredig and
Rolink, 2012). Examination of skeletal tissues in a lineage-
tracing mouse model confirmed that a substantial subpop-
ulation of the differentiated progeny of BMSCs could not
have arisen from IL-7-expressing stromal progenitors. It
should be noted that differentiated skeletal cells may ex-
press IL-7 (Long et al., 2008; Zhu et al., 2007), which would
also be revealed as EYFP positivity. However, these studies
provide unequivocal evidence linking IL-7 expression in
stromal subsets with differentiation incompetence during
normal development in vivo. Our in vivo observations
were reflected in our in vitro assays of differentiation,
where the IL-7hi immortalized BMSC clones (Y102/Y202)
exhibited limited skeletogenic potential. These in vitro as-
says are prone to artifact that could result in non-specific
detection of widely used markers of differentiation that
may not report authentic in vivo differentiation capacity,
observed for example using in vivo transplantation tech-
niques (Robey et al., 2014). Evenwith these caveats, we still
failed to detect clear evidence of differentiation ability in
Y102/Y202 CD317+ IL-7hi BMSC lines. In vivo, CD317+
cells had a dispersed bone marrow distribution and did
not generally colocalize with Cxcl12-DsRed+ perivascularCD317+ cells sorted from heterogeneous BMSCs. Mean ± SEM, n = 4
ned. *p < 0.05 by unpaired non-parametric t test.
17 and CD317+ cells. Data represent mean IL-7 levels ± SD from
*p < 0.05 by paired t test.
ed with antibodies to CD317 (red), CD31 (green) with Cxcl12-DsRed
d single-panel images shown.
ouse bone marrow showing LepR+CD317 (upper panel) and occa-
API stain.
ectroscopy, Raman shifts (H) and peak ratios (I) are shown. Raman
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stromal cells, again pointing to an alternative function
for CD317+ BMSCs, unrelated to CXCL12-mediated he-
matopoietic stem cell niche support. CD317 has a well-
defined anti-viral function acting to tether and restrict
the release of viral particles and may also trigger the viral
immune response (Hotter et al., 2013). The existence of a
marrow-resident, non-migratory, non-differentiating col-
ony-forming stromal cell type, apparently primed for
host defense, is an interesting concept. These cells could
act as first responders to pathogen invasion and/or pro-
vide low-level immune control. As IL-7 has been impli-
cated as a causative factor in autoimmunity, including
rheumatoid arthritis (Dooms, 2013), unregulated control
of CD317+ cell numbers and function may also contribute
to disease onset and progression. These findings highlight
the importance of identifying unique markers of BMSC
sub-populations and assigning function, which will
instruct strategies to analyze stromal-immune cell interac-
tion, differentiation competency, and cell selection for
safe and effective therapy.EXPERIMENTAL PROCEDURES
Primary BMSC Isolation, Culture, and hTERT BMSC
Production
All animal experiments and work involving human samples were
approved by the University of York, Department of Biology ethics
committee. Primary human BMSCs were isolated from femoral
heads obtained with informed consent during routine hip
replacement (see the Supplemental Experimental Procedures) or
as explant cultures from human tibial plateaus after routine
knee replacement. Cells were cultured in DMEM containing
15% fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml
streptomycin (changed every 3–4 days); cells were passaged at
70%–80% confluency. Cells were expanded and used between
passage 1 (p1) and p5.
The hTERT lentiviral vector was produced using ViraPower
Lentiviral Gateway Expression Kit (Invitrogen), according to the
manufacturer’s guidelines, before transduction into primary hu-
man BMSCs isolated at p3 from the femoral head of a single donor.
For selection of single cell lines, the transduced BMSCswere trypsi-
nized and plated at 10 cells/cm2. Cells were grown in BMSC
medium containing 20%HyClone serum at plating, then replaced
with freshmedia containing 15%HyClone serum every 3 or 4 days
to day 14 (until discrete single-cell colonies were visible). Single-
cell colonies were isolated and expanded.
For further information, see Supplemental Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and three tables and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2015.05.
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Figure S1. Generation and analysis of hTERT-BMSC clones, Y101, Y102, Y201 and Y202, 
Related to Figure 1.  
(A) Cumulative population doublings of hTERT-BMSC clonal lines with the original parental 
primary BMSCs.  
(B) Telomerase activity measured in the four hTERT-BMSC clones against positive (+) and negative 
(-) controls. Banding indicates PCR amplification of telomeric repeats. 
(C) Anchorage-independent growth assays in soft agarose assays using the hTERT-BMSC clones 
Y101, Y102, Y201 and Y202, alongside human diploid fibroblast (HDF) and HEK-293 cells as 
negative/positive controls respectively. Representative images of colonies taken at same 
magnification are shown after 1, 8, 14 and 21 days of culture, scale bar = 250µm. 
(D) Microscopic examination of colonies formed by Y101, Y102, Y201 and Y202 clones. Toluidine 
blue stain (A1-D1) and CellProfiler analysis (A2-D2), four representative images shown. Images are 
all taken at same scale, scale bar = 200µm. 
(E-F) Cell perimeter (E) and area (F) measurements of hTERT-BMSC clones using CellProfiler 
software. The mean ± SEM of four independent experiments examining on average 124 cells per 
experiment is shown. Data were analysed for statistically significant differences in perimeter or area 
using 1way ANOVA and Newman-Keuls multiple comparison tests between the hTERT –BMSC 
lines; *=p<0.05. 
(G) Histological ALP staining and real time qPCR gene expression analysis for ALPL of the hTERT-
BMSCs cultured in osteogenic differentiation media. Mean gene expression levels ± SEM are shown 
(average of three experiments performed in triplicate). Scale bar = 200µm. 
 
Figure S2. Bioinformatic and functional analysis of hTERT-BMSC clones, Related to Figure 2.  
(A-B) Principal component analysis of Y101, Y102, Y201 and Y202 clones against the parent BMSC 
population (FH181) and four other primary BMSC cultures (FH392, FH348, FH469 and FH359). 
(C-D) Analysis of over- (C) and under- (D) expressed metagenes in Y101, Y102, Y201 and Y202 
clones, the parent BMSC population (FH181) and four additional primary BMSC cultures (FH392, 
FH348, FH469 and FH359). 
(E) Peripheral blood mononuclear cell (PBMC) proliferation assay in the presence of hTERT-BMSCs 
at the stated ratios. Data represents average inhibition of PBMC proliferation ± SEM from five 
experiments performed in triplicate. 2way ANOVA with Sidak’s multiple comparisons between the 4 
cell lines under the different conditions were performed, revealing no significant difference at any 
cell:cell ratio. 
(F) Expression of immunomodulatory factors (IDO1, CD274, TGFB1, IL6, IL7 and CXCL10) by 
hTERT-BMSC clones following exposure to TNF and/or INF. Mean expression levels from three 
experiments performed in triplicate ± SEM are shown. Where there was significant difference in gene 
expression between control and treated cells, significant differences between the cell lines was 
assessed by 2way ANOVA and differences are indicated as brackets across the data points at at least 
p<0.05. 
 
Figure S3. Identification of EYFP-positive cells in bone/marrow of IL-7cre Rosa26-EYFP 
lineage-tracing mice, Related to Figure 3. 
(A) Distribution of EYFP-positive cells in bone. Slides were scored for the number of EYFP-positive 
cells per field as a percentage of total nucleated cells as stained by DAPI, nd = not determined. 
(B) Bone marrow cells were isolated from the femora and tibiae of IL-7cre Rosa26-EYFP mice and 
analysed by flow cytometry. The R1 gate represents live cells separated by FSC/SSC, R6 gate 
discriminates between CD45-negative, non-hematopoietic cells and CD45-positive cells, R7 gate 
identifies CD45-negative, EYFP-positive cells. Representative flow cytometric data shown.  
(C) Representative isotype control IL-7cre Rosa26-EYFP bone marrow section and bone marrow 
section showing EYFP negative control stained with the anti-GFP, alexa fluor 488 conjugated 
antibody. DAPI nuclear stain (blue). 
 
Figure S4. Validation of CD317 expression in BMSC subpopulations, Related to Figure 4. 
(A) Cumulative population doublings of four additional hTERT-BMSC clonal lines (Y204, Y205, 
Y301, Y302) with the original parental primary BMSCs (experiment performed alongside data shown 
in Figure S1A). 
(B-H) Assessment of the OAC potential of Y204, Y205, Y301 and Y302 BMSC clones; 
representative images (B, D, E, G) and quantification (C, F, H) of cells differentiated with adipogenic 
(B, C), osteogenic (D, E, F) and chondrogenic (G, H) supplements. Scale bar = 200µm in B, D & E 
whilst in G, scale bar = 2mm. Data represents average quantified values ± SD for 3 independent 
experiments performed using 6 replicates. 2way ANOVA with Sidak’s multiple comparisons were 
used to assess statistically significant differences in the three measures of differentiation between 
basal and induced conditions at each time point for each cell line. Statistical significance is denoted by 
*=p<0.05; **=p<0.01; ***=p<0.001. 
(I) Representative flow cytometric analysis of CD317 expression in Y204, Y205, Y301 and Y302 
BMSC clones. 
(J) Identification of rare CD317
+
 cells in heterogeneous primary BMSC cultures by flow cytometry, 
two example donors shown. 
(K) Microscopic examination of colonies formed by CD317
- 
and CD317
+
 cells sorted from primary 
BMSCs. Crystal violet stain (A1-D1) and CellProfiler analysis (A2-D2), four representative images 
shown. Scale bar represents 200µm 
(L) Expression of immunomodulatory factors by CD317
-
 and CD317
+
 cells sorted from primary 
BMSCs by qPCR. Mean ± SEM of gene expression in sorted cells from two donors is shown.  
(M) CD317 staining on untreated (unt) primary BMSCs or following treatment with 50ng/ml IFN-γ 
for 24hrs. Flow cytometry histograms for the two donors (left and middle) are shown and CD317 
mean fluorescence intensity (MFI) is quantified (right) following subtraction of the control staining in 
the adjacent histograms. Mean MFI ± SD of two independent experiments are shown in the histogram.  
(N) Gating strategy for flow cytometric sorting of human bone-marrow mononuclear cells (BM-
MNCs). Debris, doublets, dead cells (sytox blue positive), CD45-positive and CD31-positive cells 
were removed. Percentages shown are the cell populations of the live (sytox blue negative) cells. Data 
shown are representative of two independent experiments using two separate preparations of primary 
human BM-MNCs. 
(O) Representative flow cytometric analysis of CD317 expression in BM-MNCs: two donors are 
shown with the percentage of total live cells negative for CD45 and CD31 but expressing CD317 
displayed.  
(P) Representative staining of mouse bone marrow sections. Scale bar represents 50µm. Blue = 
nuclear DAPI, green = CD31, red = CD317 and white = Cxcl12-DsRed. Single channel and merged 
overlay images are shown. 
(Q) Representative antibody isotype control for the donkey anti-rabbit antibody used as a secondary 
antibody to reveal CD317 staining on mouse bone marrow sections in Fig 4F/G. Scale bar represents 
50µm. Blue = DAPI; Red = isotype control plus donkey anti-rabbit secondary antibody. 
  
SUPPLEMENTAL TABLES 
 
Target Conjugate Supplier Catalogue number 
hCD45 FITC eBioscience 11-9459 
hCD166 PE BD Pharmingen 559263 
hCD44 FITC BD Pharmingen 555478 
hCD90 None eBioscience 14-0909 
hCD105 APC eBioscience 17-1057 
hCD29 Purified (none) BD Pharmingen 556048 
hCD73 Purified (none) BD Pharmingen 550256 
hCD34 FITC Miltenyi Biotec 130-081-001 
hCD317 PE BioLegend or eBioscience 348406 or 12-3179 
hCD271 FITC Miltenyi Biotec 130-091-917 
hCD51/CD61 None BD Pharmingen 555504 
hPDGFRα None Santa Cruz Biotechnology sc-21789 
hCD146/MCAM None Abcam ab24577 
hICAM None BD Pharmingen 555510 
hCD274 APC eBioscience 17-5983 
hCD295 PE R&D Systems FAB867P 
hCD31 Alexa Fluor 647 BD Pharmingen 558094 
hIL-7 None R&D Systems MAB207 
mCD317 None Novus Biologicals NBP2-27154SS 
mCD295 Biotin R&D Systems BAF497 
mPerilipin A/B None Bioss bs-6765R 
mIgG2b, isotype control PE Biolegend 400313 
mIgG1, isotype control None eBioscience 14-4714 
Goat anti-mouse-IgG Alexa Fluor 488 Invitrogen A11001 
Goat anti-rabbit IgG Alexa Fluor 488 Invitrogen A11008 
Donkey anti-rabbit-IgG Alexa Fluor 647 Invitrogen A31573 
Anti-GFP tag Alexa Fluor 488 Invitrogen A21311 
 
Table S1. Antibodies used for flow cytometry. Key: h=human; m=mouse.  
Peak assignment cm
-1 
Peak Identification* 
717.1 Lipids 
779.3 DNA/RNA nucleic acids 
849.8 Proteins/amino acids 
966.0 DNA/RNA nucleic acids 
999.6  Phenylalanine 
1088.6 PO
-
2 stretch DNA 
1203.7 Amide III and other amino acids/nucleic acids 
1239.4  Amide III 
1334.8  Lipids/nucleic acids/proteins 
1447.3  Proteins and lipids 
1657.8  Lipids 
 
Table S2. Mean Raman peak assignments corresponding to the averaged spectra per cell line (Figure 
4H, I); maximum uncertainties in the peak measurements are ± 0.8 cm
-1
, corresponding to the spectral 
resolution of the instrument. 
 
 
 
 
  
Gene Target Primer sequence 
Peroxisome proliferator activated receptor 
(PPAR)-γ forward 
GGCTCCATGACAAGGGAGTTTC 
PPARγ reverse AACTCAAACTTGGGCTCCATAAAG 
Lipoprotein lipase (LPL) forward GAGGTACTTTTCAGCCAGGATGTAAC 
LPL reverse AGCTGGTCCACATCTCCAAGTC 
Ribosomal protein S (RPS)27a forward TGGATGAGAATGGCAAAATTAGTC 
RPS27a reverse CACCCCAGCACCACATTCA 
Alkaline Phosphatase (ALPL) forward GGGAACGAGGTCACCTCCAT 
ALPL reverse TGGTCACAATGCCCACAGAT 
RUNX2 forward GGTTAATCTCCGCAGGTCAC 
RUNX2 reverse GTCACTGTGCTGAAGAGGCT 
SOX9 forward TTCCGCGACGTGGACAT 
SOX9 reverse TCAAACTCGTTGACATCGAAGGT 
  
Table S3. qPCR primer sequences  
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Primary BMSC isolation and culture 
Primary human BMSCs were isolated from femoral heads obtained with informed consent during 
routine hip replacement, as previously described (Dyson et al., 2007; Etheridge et al., 2004), or as 
explant cultures from human tibial plateaus after routine knee replacement surgery. Cells were 
cultured in DMEM containing 15% FBS, 100U/mL penicillin and 100µg/mL streptomycin, which 
was changed every 3–4 days; cells were passaged at 70-80% confluency. Cells were expanded and 
used between passages (p)1 and p5. 
 
hTERT BMSC production 
The hTERT lentiviral vector was produced using the ViraPower Lentiviral Gateway Expression Kit 
(Invitrogen) according to manufacturer’s guidelines, and as previously described (Saleh et al., 2012) 
before transduction into primary human BMSCs from a single donor. After clonal selection, the 
human telomerase gene was subcloned from pCI-neo-hEST2 (Addgene, courtesy of Robert 
Weinberg) into the pENTR 1A backbone provided using restriction enzyme digestion and ligation. 
After appropriate screening, an LR recombination reaction was performed, successfully incorporating 
the hTERT gene into pLent6/V5-DEST lentiviral vector.  
pLenti6/V5-DEST-hTERT lentiviral stocks were produced using 293FT cells according to 
manufacturer’s instructions. 24hrs after lipofectamine transfection of pLenti6/V5-DEST-hTERT and 
viral packaging mix, culture media was replaced with 5ml fresh culture medium to concentrate viral 
particles. Lentivirus-containing medium was harvested 48hrs post-transfection, and lentiviral stocks 
were titered using the Lenti-X qRTPCR Titration Kit (Clontech).   
BMSCs were transduced with pLenti6/V5-DEST-hTERT in the presence of 6µg/ml polybrene. After 
16hrs the lentivirus-containing medium was removed and replaced with fresh BMSC media. After a 
further 24hrs, the cells were passaged and 2µg/ml blasticidin was added to the culture media. Media 
was replaced every 3-4 days with fresh blasticidin-containing medium for 12 days, when no living 
mock-transfected cells remained. To select single cell lines the transduced BMSCs were trypsinized 
and plated in 10cm plates at 10 cells/cm
2
. Cells were grown in BMSC medium containing 20% 
HyClone serum for plating out the cells, then replaced with fresh BMSC medium containing 15% 
HyClone serum every 3/4 days for 14 days (until discrete single cell colonies were visible). Single cell 
colonies were isolated using cloning cylinders, silicone grease, and trypsin-EDTA and then 
transferred to wells of 24-well plates. Once the cells reached 70% confluence they were passaged into 
6-well plates, then 25cm
2
 flasks, and finally 75cm
2
 flasks for continued expansion. Cells were counted 
at each passage to determine population doubling time and maintained for continued culture in 
DMEM containing 10% FBS and antibiotics. Telomerase activity in hTERT-BMSCs was assessed 
using the TRAPeze® gel-based telomerase detection kit (Millipore) according to manufacturer’s 
guidelines. Analyses using CellProfiler software were performed according to the designer 
instructions (www.cellprofiler.org). 
 
In vitro hTERT BMSC differentiation  
In vitro induction of BMSC differentiation was performed as previously outlined (Etheridge et al., 
2004; Hoogduijn et al., 2006; Saleh et al., 2011). Osteogenic differentiation was induced for up to 21 
days with the addition of 5mM β- -ascorbic acid phosphate and 10nM 
dexamethasone to growth media. Osteogenesis was assessed by both histological staining with 
alizarin red and quantitative elution of the stain alongside quantitative assays for alkaline phosphatase 
(ALP) activity (Cook et al., 2014; Hoogduijn et al., 2006) and gene expression analyses for Runx2 
and ALP. Adipogenic differentiation was induced with 0.5mM isobutyl-methylxanthine, 1µg/ml 
insulin, 100µM indomethacin and 1µM dexamethasone for up to 21 days. Lipid accumulation was 
examined and quantified by Oil Red O staining (Cook et al., 2014) and gene expression analyses for 
PPARγ and LPL were performed. Micromass pellet cultures were utilized for chondrogenesis assays. 
Briefly, cells were trypsinized and resuspended to 2x10
7
 cells/ml in serum-free media; 20µl cell 
suspension was placed in the middle of a culture well and allowed to adhere at 37°C for 3h. Wells 
were flooded with serum-free media containing 50µg/ml L-ascorbic acid phosphate, 100nM 
dexamethasone, 40µg/ml L-proline, 1% ITS
+
, with or without TGF-β; medium was changed twice 
weekly. Chondrogenic differentiation was assessed using 9 day micromass cultures and potential was 
indicated through an early cell condensation phenotype (Johnson et al., 2012). After 1, 6 or 9 days of 
culture, cells were fixed in 100% methanol (-20°C, 30 mins), then incubated overnight with 0.5% 
alcian blue 8GS in 1M HCl (pH 0.2 to selectively stain highly sulphated glycosaminoglycans (GAGs) 
associated with cartilage tissue). Cells were washed extensively with distilled water before 
stereomicroscope visualisation. Specific GAG-associated stain was eluted from pellets by 6M 
guanidine incubation for 3 hours with rocking; supernatant absorbance was measured at 630nm. Total 
GAG content (pellet associated and secreted) for each cell line following chondrogenic induction was 
measured by the Blyscan glycosaminoglycan assay (Biocolor Ltd, UK) according to the 
manufacturer’s instructions. Gene expression analyses by qPCR for the early chondrogenic marker 
Sox9 were also performed. 
 
Flow cytometry and cell sorting 
Cell surface marker profiles were assessed on a CyAn flow cytometer and analyzed using Summit 
software (v4.3; Beckman Coulter). Cells were detached from culture plastic by incubation with PBS 
containing 0.2% BSA and 5mM EDTA, and stained with either directly conjugated primary 
antibodies, or successive incubations with optimised concentrations of primary antibody and an 
appropriate fluorescent-conjugated secondary antibody. All antibodies are listed in Table S1. For cell 
sorting, BMSCs were processed and stained as above then sorted on a MoFlo Astrios high-speed, 
sterile cell sorter (Beckman Coulter). Cryopreserved, primary human bone marrow mononuclear cells 
(BM-MNCs) were purchased from Lonza (Belgium); both healthy donors were male Caucasians, 
donor one was 21 years of age, donor two was 22. Cells were thawed according to the Poietics 
protocol, rested for an hour before staining for 40mins with optimised concentrations of CD45, CD31 
and CD317 antibodies or equivalent concentrations of isotype controls before sorting. Cells were also 
extracted from femora and tibiae bone marrow of IL-7cre Rosa26-EYFP mice and incubated with 
ACK buffer to lyse any red blood cells prior to flow cytometric analysis. CD317 staining was also 
assessed on primary cells after 50ng/ml recombinant human IFN-γ (PeproTech EC Ltd, UK) 
treatment for 24 hours. 
 
Anchorage independent growth assay 
Anchorage independent growth assays as an assessment of tumorigenic potential were performed on 
hTERT BMSC-lines alongside HEK-293 cells as positive controls and human dermal fibroblasts as a 
negative control. Cells were seeded into media containing 0.45% agarose in plates coated with 0.75% 
agarose and cultured for up to 21 days before imaging by brightfield microscopy. 
 
RNA isolation and gene expression analysis 
Total RNA was isolated from 80-90% confluent cultures using Macherey-Nagel Nucleospin RNA II 
kit. RNA quality was determined with the Agilent 2100 Bioanalyzer nano chip; high quality RNA 
samples were labelled using Agilent One Color Quick Amp labelling. Samples were processed for 
genome-wide gene expression analysis using the Agilent SurePrint G3 Human Gene Expression 
8x60K v2 Microarray kit; triplicate arrays were performed on each cell line. All quality control 
checks met required standards. Data were analyzed using GeneSpring version 12.1 software (Agilent 
Technologies), using initial one-way ANOVA with controlling for multiple testing. This allowed for 
p-value adjustment lowering false discovery rate whilst maintaining sensitivity. Genes with a 
minimum two-fold difference in expression level and an adjusted p-value of <0.05 were considered 
differentially expressed. Subsequent pathway analysis was performed on lists of differentially 
expressed genes within the GeneSpring software. Additional analyses were performed using the 
statistical programming language R and the Bioconductor package limma. 
  
Quantitative real-time PCR (qPCR) was performed using two protocols; the first used 500ng cDNA 
with the StepOnePlus™ Real-Time PCR System, TaqMan Universal PCR Master Mix and the assay-
on-demand primer/probes for IDO1 (Hs00158027.m1), IL6 (Hs00174131.m1), IL7 
(Hs00174202.m1), IL10 (Hs00174086.m1), TGFB1 (Hs00171257.m1), CD274 (Hs00204257.m1), 
CXCL10 (Hs00171042.m1) and B2M (Hs00187842.m1) (all Applied Biosciences, Foster City, CA, 
USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA served as endogenous control 
for normalization (Hs99999905.m1; Applied Biosciences). Intra- and inter-assay variations were 
determined by negative controls and positive reference samples. Changes in target gene expression 
relative to GAPDH were quantified using the comparative CT method. The second method used the 
SYBR green system and optimised amounts of cDNA reverse transcribed using superscript II 
(Invitrogen, UK) from 1µg of RNA isolated from primary BMSCs differentiated along the osteogenic, 
adipogenic or  chondrogenic lineages using Trizol/chloroform extraction (Life Technologies, UK). 
cDNA was amplified using Fast SYBR Green Master Mix (Life Technologies) and optimised primers 
(Table S3) for analysis of adipogenic genes (peroxisome proliferator-activated receptor gamma and 
lipoprotein lipase), osteogenic genes (alkaline phosphatase and RUNX2) or a chondrogenic gene 
(SOX9) using the StepOne real-time PCR system. Gene expression levels were quantified using the 
comparative CT (ΔΔCt) method and StepOne software v2.3 relative to the expression of the 
housekeeping gene RPS27a and normalized to d7 basal levels. 
 
Agilent microarray data processing 
Preprocessing of the microarray data was carried out using the statistical programming language R 
and the Bioconductor package limma. Firstly, background correction with optimal offset value was 
applied to the arrays to minimize signal related to non-specific fluorophore binding. The optimal 
offset value was evaluated by identifying which value stabilized the variances of probeset intensities 
the most. Quantile normalization was then applied to the arrays, which resulted in each array having 
the same empirical distribution of probeset intensity values, removing systematic variation from the 
data and scaling it so comparisons could be made between them. The values were then transformed by 
log2 to control for variability in both highly and poorly expressed genes. Uninformative data such as 
control probesets and genes with low variance were also removed to decrease the false discovery rate 
(FDR). Lastly, the average expression levels from each of the replicates were collected into a global 
expression dataset. 
Microarray data can be found on ArrayExpress: E-MTAB-3511 (release date: 03-August-2015). 
 
Differential gene expression analysis 
Differentially expressed genes were defined as those which exhibited a log fold-change of greater 
than two. The statistical significance of this differential expression was evaluated using a moderated t-
test, known as Empirical Bayes. Instead of calculating an estimate of the variance for each gene, this 
moderated version calculates a global variance from the variances for all genes in the dataset. This is 
combined with an average of the variance for each gene producing a statistical test value that has a t-
distribution. The Bioconductor package limma was used to calculate this log fold-change and 
significance value by applying a linear model to the probe set intensities for each gene using a least 
squares method. Limma also employed the Benjamini and Hochberg algorithm to control for the 
effects of multiple testing. This procedure allowed for the adjustment of the p-values and the lowering 
of the false discovery rate whilst keeping the sensitivity for true positive results. Genes with a two-
fold difference in expression levels and with an adjusted p-value of ≤0.05 between any pair of cell 
lines in the dataset were considered as significantly differentially expressed. The differentially 
expressed genes limma outputs were then collected into a differential expression dataset for use in 
subsequent analyses. 
 
Sample and gene clustering algorithms 
A preliminary insight into the variation of gene expression profiles between cell lines was achieved by 
performing principal component analysis (PCA) on the differential expression dataset using the R 
CRAN package stats. This approach reduces the dimensionality of the dataset into two orthogonal 
variables, visualised as a two-dimensional scatterplot of the cell lines. Cell lines that cluster close 
together in two-dimensional space are considered to have more similar expression profiles than those 
further away. 
 
SOM-mapping of global expression profiles 
Self-organizing map (SOM) machine learning was applied to the global expression dataset using the 
R CRAN package oposSOM (Wirth et al., 2011). This unsupervised learning method uses neural 
networks to reduce high dimensional data onto a two-dimensional mosaic. Each tile on the mosaic 
represents a metagene consisting of mini-clusters of genes with similar expression profiles. Genes are 
assigned to clusters using the minimum Euclidian distance and metagenes with similar expression 
profiles are positioned next to each other. Because the same metagene is assigned to the same tile in 
SOMs across all samples, direct visual comparisons of global expression can be made and areas of 
notable over- or under- expression are readily observed. After running the analysis, oposSOM outputs 
a SOM for each cell line, a combined SOM of over- and under- expressed metagene hotspots, 
including a list of genes which contribute to those metagenes and their relative expression in each cell 
line. 
 
Gene set over-representation analysis 
Gene set over-representation analysis was used to help define the functional nature of the respective 
spots. For each of the spots the degree of over-representation of 1454 pre-defined gene sets was 
measured using the hypergeometrical distribution (Wirth et al., 2011). This assigns the probability 
that members of a certain gene set are present in a list of genes compared against the random chance 
of their appearance independent of expression values. Gene sets contain lists of genes which have 
been shown to act in the same pathway or appear to be coexpressed. An over-representation p-value is 
then used to evaluate the significance of over-representation of each gene set to each metagene. The 
hypergeometrical distribution then ranks the list of gene sets by decreasing significance of over-
representation for the spots. In addition, gene ontologies were used to describe the attributes of each 
gene product in these hotspots. Gene ontologies provide a comprehensive and unified way of 
annotating gene products with i) the biological process to which they contribute ii) their functional 
biochemical activity iii) the cellular component where they are active (Ashburner et al., 2000). Using 
a hypergeometrical distribution, the statistical over-representation of these terms with regards to the 
global expressed set was also calculated. Again, oposSOM was used to carry out this analysis, and 
given the row names of the expression dataset are labelled using ENSEMBL gene IDs is 
automatically performed when the function is called. 
 
Immunofluorescent staining for IL-7 
To identify IL-7 immunopositivity in hTERT-BMSCs, 2x10
4 
cells were seeded onto coverslips, 
allowed to adhere overnight then fixed in 4% PFA for 5mins at 21°C before permeabilization with 
0.1% Triton X-100 in PBS and blocking of endogenous peroxidase activity with 1% H2O2. All future 
steps were performed at room temperature in a humidified chamber in the presence of 1% blocking 
reagent supplied with the tyramide signal amplification kit. Extensive washes were performed 
between antibodies; all reagents were from Invitrogen unless otherwise stated. Samples were initially 
blocked for 30mins in PBS containing 1% blocking reagent before incubations for 60mins with 
optimised concentrations of either mouse anti-human IL-7 primary antibody (R&D clone 
7417/catalogue number MAB207) or an IgG1 isotype control. Coverslips were incubated with 1:200 
biotinylated anti-mouse secondary antibody for 30mins before incubation with 1:100 diluted 
horseradish peroxidase for 45mins. Alexa Fluor-647 conjugated tyramide was 1:100 diluted in 
amplification buffer and incubated with the samples for 5mins. Finally, samples were extensively 
washed before mounting in Prolong gold containing DAPI and imaged using an LSM710 invert 
confocal microscope (Carl Zeiss). 
 
In vivo IL-7 lineage tracing 
IL-7cre Rosa26-EYFP mice were bred under pathogen free conditions at the University of York 
(Repass et al., 2009). All work was in accordance with ethical approvals from the University of York 
and Home Office License 60/4169. For lineage tracing experiments, tissues from IL-7cre Rosa26-
EYFP mice were fixed in 4% PFA overnight and placed at room temperature in 30% sucrose solution 
for 15mins followed by 15% sucrose overnight at 4°C. Tissues were then coated with 10% polyvinyl 
alcohol (PVA) and frozen in cooled isopropanol on dry ice. They were then fully mounted in 10% 
ostat, slide-mounted and observed by fluorescence 
microscopy. 
 
Immunohistochemistry 
Bone samples from the femurs of 11- or 12-week old female hybrid C57BL/Ka x C57BL/6 mice 
(derived from in-house crossing of Cxcl12
tm2.1Sjm
/J (The Jackson Laboratory) and wild-type C57BL/6 
mice) or IL-7cre Rosa26-EYFP and non-EYFP expressing mice were used. These mice express 
DsRedE2 under control of the Cxcl12 promoter (Ding and Morrison, 2013) or IL-7 EYFP, 
respectively. Samples were fixed overnight at 4°C in 4% paraformaldehyde/75mM lysine/10mM 
periodate fixative. Bones were decalcified for 3 days in 10% EDTA, 0.1M Tris, pH7.2 at 4°C with 
agitation before overnight incubation in 30% sucrose in PBS at 4°C and embedding in optimal cutting 
temperature embedding media (Tissue-Tek). 5µm sections were cut, applied to slides and blocked for 
1hr at room temperature in staining buffer (PBS + 0.05% BSA + 5% species specific serum) before 
staining with optimised concentrations of primary antibodies in staining buffer at 4°C overnight. 
Three five-minute washes (PBS + 0.05% BSA) were performed before slides were incubated with 
optimised concentrations of relevant secondary antibody for 1hr at RT. Where indicated, anti-GFP tag 
antibody was applied for 1hr. Three further washes, DAPI counterstaining and prolong gold mounting 
(Invitrogen) were performed before imaging using an LSM710, LSM780 or LSM 510 confocal 
microscopes (Carl Zeiss) and image analysis with Zen 2012 (blue edition) software (Carl Zeiss). 
 
ELISA for IL-7 secretion 
Cells were seeded into 6 well plates at 2x10
4
 cells/cm
2
 and left to adhere overnight. Culture media 
was replaced with 2ml fresh media; 24h later the quantity of IL-7 in the supernatant was measured 
using the Quantikine HS Human IL-7 Immunoassay (R&D systems) according to the manufacturer’s 
guidelines, and compared against medium alone. 
 
Peripheral blood mononuclear cell (PBMC) proliferation assay 
PBMCs were incubated with the hTERT-BMSCs at ratios of 1:5, 1:10, 1:20 and 1:40. PBMC 
proliferation was quantified by detection of 
3
H-thymidine incorporation into the PBMCs after three 
days of stimulation with anti-CD3 anti-CD28 antibodies.  
 
Raman Methods 
The hTERT BMSCs and CD317+ cells were seeded at 5x10
4
 cells per CaF2 microscope slide; slides 
were incubated in growth media with 0.1% amphotericin B for 24h before replacement with DMEM 
containing 0.5% FBS and another 24h incubation for G0 synchronisation. Before Raman analysis, 
slides were PBS rinsed twice and air-dried. Raman spectra were collected using a HORIBA XploRA 
micro-Raman instrument with 532nm laser wavelength and x100 objective (NA = 0.9) in confocal 
setting. Spectra were acquired ambiently using 45s laser exposure resulting in 3.5mW power at the 
sample. Each measurement was obtained using a 2400 lines/mm diffraction grating, with the results 
averaged over 2 spectral acquisitions over the ‘finger-print’ range (600cm-1 to 1800cm-1). Raman 
spectra were collected from hTERT BMSC lines using 20 randomly selected cells, with five randomly 
selected points taken in the nucleus of each cell. The resulting 100 spectra per BMSC line were 
baseline-corrected and averaged so that a representative spectrum of each BMSC population was 
obtained. For the CD317+ cell line, a Raman spatial map consisting of 172 spectra across the nucleus 
was acquired. These spectra were baseline-corrected and averaged to obtain a representative spectrum 
of the individual CD317+ cell under investigation. To prevent laser-induced cell damage, Raman 
spectra were monitored during real-time data acquisition, with optical inspection also being performed 
after each Raman measurement. All spectra were collected using the LabSpec 5 software (HORIBA). 
Baseline-correction was performed to each spectrum using an interval linear fitting method obtained 
in the ‘Raman tool set’ software (Candeloro et al., 2013). Further analysis on the averaged spectra, 
including individual peak baselines and Gaussian peak fitting, was conducted using IGOR Pro 6.32. 
Raman markers were determined from the set of two-peak intensity ratios derived from key peaks in 
the averaged cell spectra.  
 
Data Analysis 
Data were analysed in GraphPad Prism v6.05; statistical analyses using 2way ANOVA followed by 
Sidak’s multiple comparisons, paired t-test or 1way ANOVA with relevant multiple comparison test 
were used, where indicated. 
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